Klepper J, Leiendecker B, Bredahl R, Athanassopoulos S, Heinen F, Gertsen E, Flörcken A, Metz A, Voit T
Department of Pediatric Neurology, University of Essen, Essen, Germany.
J Inherit Metab Dis. 2002 Oct;25(6):449-60. doi: 10.1023/a:1021238900470.
The ketogenic diet is a rational treatment for pyruvate dehydrogenase complex deficiency (McKusick 312170) and GLUT1 deficiency syndrome (McKusick 138140). An increasing number of patients are diagnosed in early infancy, but few data are available on the introduction of a ketogenic diet in this age group. GLUT1 deficiency syndrome was suspected in four infants presenting with seizures and unexplained hypoglycorrhachia. A ketogenic diet was introduced at 6-28 weeks of age. Ketosis was initiated by fasting, monitored by bedside blood glucose and 3-hydroxybutyrate determinations, and was maintained successfully using supplemented carbohydrate-free infant formula and emulgated triglycerides. All patients developed ketosis within 24 h. 3-Hydroxybutyrate concentrations available at the bedside correlated inversely with the base excess. At glucose levels < or = 40 mg/dl patients remained asymptomatic in the presence of ketones. The ketogenic formula was tolerated well, parental compliance was good, and all patients remained seizure-free on the diet. GLUT1 deficiency was confirmed in two patients; the diet was discontinued in the other two patients. In one infant, failure to thrive on medium-chain triglycerides was effectively reversed using long-chain triglycerides. Urine dipstick analyses failed to detect ketosis in another infant. Adverse effects of the diet were limited to renal stones in one patient. The ketogenic diet can be introduced and maintained successfully in young infants using long-chain fat emulsion. Monitoring 3-hydroxybutyrate at the bedside was useful for metabolic control and superior to urine dipstick analysis. Seizure control was effective and adverse effects were limited, but evaluation of the long-term effects of the ketogenic diet in this age group must await ongoing studies.
生酮饮食是丙酮酸脱氢酶复合物缺乏症(麦库西克312170)和葡萄糖转运蛋白1缺乏综合征(麦库西克138140)的合理治疗方法。越来越多的患者在婴儿早期被诊断出来,但关于这个年龄组引入生酮饮食的数据很少。4名出现癫痫发作和不明原因低血糖性脑脊液的婴儿被怀疑患有葡萄糖转运蛋白1缺乏综合征。在6至28周龄时引入生酮饮食。通过禁食启动酮症,通过床边血糖和3-羟基丁酸测定进行监测,并使用补充的无碳水化合物婴儿配方奶粉和乳化甘油三酯成功维持。所有患者在24小时内出现酮症。床边可获得的3-羟基丁酸浓度与碱剩余呈负相关。在血糖水平≤40mg/dl时,患者在有酮的情况下仍无症状。生酮配方耐受性良好,家长依从性良好,所有患者在饮食期间均无癫痫发作。2名患者确诊为葡萄糖转运蛋白1缺乏;另外2名患者停止了饮食。在1名婴儿中,使用长链甘油三酯有效逆转了中链甘油三酯导致的生长发育不良。另1名婴儿的尿试纸分析未能检测到酮症。饮食不良反应仅限于1名患者出现肾结石。使用长链脂肪乳剂可在幼儿中成功引入并维持生酮饮食。床边监测3-羟基丁酸有助于代谢控制,优于尿试纸分析。癫痫控制有效,不良反应有限,但对这个年龄组生酮饮食长期影响的评估必须等待正在进行的研究。